04-c-„FŒ{›xŒ¾-4.01
|
|
|
- たみじろう ますはら
- 9 years ago
- Views:
Transcription
1 544( 56 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec * *
2 Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 57 ) % Escherichia coli Pseudomonas aeruginosa Enterococcus faecalis E. coli P. aeruginosa E. faecalis E. coli 40% E. coli E. coli P. aeruginosa E. faecalis P. aeruginosa E. coli P. aeruginosa E. faecalis
3 546( 58 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 1 23) I. 1. Fig % (236/565) 58.2% (329/565) % (30/236) 26.7% (8/30) 60.0% (18/30) 13.3% (4/30) % (84/236) % (158/329) % 2. Fig. 2 Escherichia coli 51.7% 23.5% 13.6% Pseudomonas aeruginosa 2.9% 7.9% 13.6% Enterococcus faecalis 8.8% 12.6% 21.5% 3. Fig. 3 Fig. 3 1 E. coli %, % %, % E. faecalis %, %, %, % Fig. 3 2 E. coli %, %, %, % E. faecalis %, %, %, % E. coli P. aeruginosa Fig E. faecalis %, % E. coli, P. aeruginosa, S. aureus
4 Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 59 ) Fig
5 548( 60 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. Fig
6 Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 61 ) Fig
7 550( 62 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec Fig E. coli 50.3%54.0% P. aeruginosa 2.0% 4.6% E. faecalis 9.2% 8.0% E. coli E. faecalis 25.7%, 12.4% 13.2% E. coli P. aeruginosa S. aureus 6.4%, 6.4% 15.1%, 7.5% P. aeruginosa 10.3% 18.6% E. coli S. aureus 16.8%, 11.2%, 8.6%, 7.1% E. faecalis 20.6% 22.9% 5. Fig E. coli E. faecalis 33.3% 14.8% E. coli 57.0% 6 Klebsiella spp., Proteus spp., Enterobacter spp., P. aeruginosa, S. aureus, E. faecalis E. coli, E. faecalis, P. aeruginosa 22.3%, 13.9%, 11.4% E. coli, E. faecalis, S. aureus 25.0%, 11.0%, 7.4% E. faecalis 25.0% P. aeruginosa 14.5% E. coli 17.0% E. faecalis 13.2% II. 1 23) %, % E. coli
8 Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 63 ) Fig
9 552( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. Fig
10 Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 65 ) P. aeruginosa E. faecalis P. aeruginosa E. coli % E. faecalis E. coli E. faecalis E. coli P. aeruginosa E. faecalis E. faecalis 55.6% E. coli P. aeruginosa E. coli P. aeruginosa E. coli Klebsiella spp., P. aeruginosa, E. faecalis E. coli, E. faecalis P. aeruginosa E. coli, E. faecalis E. coli P. aeruginosa P. aeruginosa E. faecalis E. coli, P. aeruginosa, E. faecalis 1) E.coli, Klebsiella, Citrobacter Proteus Jpn. J. Antibiotics 34: , ) Escherichia coli, Klebsiella, Citrobacter Proteus Jpn. J. Antibiotics 36: , ) Jpn. J. Antibiotics 37: , ) Jpn. J. Antibiotics 38: , ) Jpn. J. Antibiotics 39: , ) Jpn. J. Antibiotics 40: , ) Jpn. J. Antibiotics 42: , ) Jpn. J. Antibiotics 43: , ) Jpn. J. Antibiotics 45: , ) Jpn. J. Antibiotics 48: , ) Jpn. J. Antibiotics 48: , ) Jpn. J. Antibiotics
11 554( 66 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 48: , ) Jpn. J. Antibiotics 48: , ) Jpn. J. Antibiotics 48: , ) Jpn. J. Antibiotics 49: , ) Jpn. J. Antibiotics 50: , ) Jpn. J. Antibiotics 51: , ) Jpn. J. Antibiotics 52: , ) Jpn. J. Antibiotics 53: , ) Jpn. J. Antibiotics 54: , ) Jpn. J. Antibiotics 55: , ) Jpn. J. Antibiotics 56: , ) Jpn. J. Antibiotics 57: , 2004 COMPARATIVE STUDIES ON ACTIVITIES OF ANTIMICROBIAL AGENTS AGAINST CAUSATIVE ORGANISMS ISOLATED FROM PATIENTS WITH URINARY TRACT INFECTIONS (2003) II. BACKGROUND OF PATIENTS YOSHIAKI KUMAMOTO*, TAIJI TSUKAMOTO, MASANORI MATSUKAWA and YASUHARU KUNISHIMA Department of Urology, Sapporo Medical University School of Medicine (*: a honorary professor at present) TAKAOKI HIROSE Department of Urology, Hokkaido Social Insurance Hospital OSAMU YAMAGUTI and KEI ISHIBASHI Department of Urology, Fukushima Medical University TATSUO SUZUTANI Department of Microbiology, Fukushima Medical University SHIRO SHIGETA Division, Bureau of Hospital Administration, Fukushima Prefectural Goverment HIROSHI YOSHIDA and YUUJI IMAFUKU Department of Clinical Laboratory Medicine, Fukushima Medical University
12 Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS ( 67 ) MASARU MURAI Department of Urology, Keio University School of Medicine KIYOAKI WATANABE, YOSHIO KOBAYASHI and HIROSHI UCHIDA Central Clinical Laboratories, Keio University School of Medicine SEIJI MATSUDA Department of Gynecology, Koto Hospital SHINICHI SATO Department of Clinical Laboratories, Koto Hospital TOSHITSUGU OKA and MASAYA KITAMURA Department of Urology Osaka National Hospital YOSHINORI FUKUHARA Department of Clinical Laboratories, Osaka National Hospital SADAO KAMIDONO Division of Urology, Kobe University Graduate School of Medicine SOICHI ARAKAWA Department of Surgical Operation, Kobe University Hospital MAKOTO FUJIME and KAZUHIKO FUJITA Department of Urology, Juntendo University School of Medicine HIROMI KUMON and KOICHI MONDEN Department of Urology, Okayama University Graduate School of Medicine and Dentistry JUN IGARI Urayasu Hospital, Juntendo University School of Medicine TOYOKO OGURI Department of Clinical Laboratories, Juntendo University Hospital KEIZO YAMAGUCHI and NOBUHIKO FURUYA Department of Microbiology, Toho University School of Medicine TAKASHI DEGUCHI and SATOSHI ISHIHARA Urological Devision, Disease Control Course, Gifu University Graduate School of Medicine HIROSHI OOE Department of Urology, Kyoto Second Red Cross Hospital TETSURO MATSUMOTO and KOICHI TAKAHASHI Department of Urology, School of Medicine, University of Occupational and Environmental Health SEIJI NAITO, TOSHIHISA EGASHIRA, and TAKATOSHI KONISHI Department of Urology, Kyushu University Graduate School of Medicine SHIGERU KOHNO Second Department of Internal Medicine, Nagasaki University School of Medicine YOICHI HIRAKATA, AKIRA KONDO, JUNICHI MATSUDA and MICHIKO NAKANO Department of Laboratory Medicine, Nagasaki University Hospital of Medicine and Dentistry MINEKO NISHIKAWA Department of Clinical Laboratory, Kyoto Second Red Cross Hospital YUMIKO SUZUKI Department of Laboratory, Yamada Evidence Research
13 556( 68 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. Seven hundred and nineteen bacterial strains isolated from 565 patients diagnosed as having urinary tract infections (UTIs) in 14 institutions in Japan were collected between August 2002 and July The frequency of bacteria isolation divided with patient clinical background was compared. The clinical background investigated included sex, age, type of infections, timing of antibiotics administration, and presence or absence of surgery affecting a decrease in defense against infection. The bacterial strains were divided with the age and sex of the patients and the types of infections. In males, the number of patients aged less than 50 years was few and the complicated UTIs without indwelling catheter was observed most frequently. Number of patients aged years was greater in female than male. In all of ages except 0 9 and years, the ratio of the uncomplicated UTIs was high, accounting for % of all types of infections. In the present time, the bacteria most frequently isolated were Escherichia coli, Pseudomonas aeruginosa and Enterococcus faecalis also were relatively frequently isolated. E. coli was most frequently isolated from the uncomplicated UTIs, and P. aeruginosa and E. faecalis were frequently isolated from the complicated UTIs with indwelling catheter. With respect to the relation of these results to the age of the patients, in the uncomplicated UTIs, the isolation frequency of E. coli was the highest in all age groups, accounting for 40% or higher. In the complicated UTIs without indwelling catheter, the isolation frequency of E. coli decreased with aging of the patients but still was the highest in all age groups. In the complicated UTIs with indwelling catheter, the isolation frequency of E. coli was lower than in the uncomplicated UTIs in all age groups and P. aeruginosa and E. faecalis were more frequently isolated. In comparison of causative bacteria in UTIs between before and after the administration of antibiotics, P. aeruginosa increased after the administration in any types of UTIs. In comparison of causative bacteria in UTIs with or without surgery, E. coli was more frequently isolated in the patients without surgery, while P. aeruginosa and E. faecalis were more frequently isolated in the patients with surgery in any UTIs.
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic
COMPARATIVE CLINICAL EFFECT OF AMIKACIN AND GENTAMICIN ON COMPLICATED URINARY TRACT INFECTIONS BY DOUBLE-BLIND METHOD Tsuneo Nishiura and Yukimichi Kawada Department of Urology, Gifu University School
366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
Fig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
Table 1. Influence of urine ph on MBCs of new quinolones against Escherichia coli NIHJ JC-2 and Pseudomonas aeruginosa 18S; MBCs in urine were compared with those in Miieller-Hinton broth. Table 2. Influence
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
A comparison of abdominal versus vaginal hysterectomy for leiomyoma and adenomyosis Kenji ARAHORI, Hisasi KATAYAMA, Suminori NIOKA Department of Obstetrics and Gnecology, National Maizuru Hospital,Kyoto,
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad
Key words: Female with bladder irritability, Subjective symptoms, Pyuria, Bacteriuria Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution
CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
VOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3
VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
Table1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
Table 1 Classification of female patients with vealcal irritating symptom by their signs Urination pain with other vesical irritability or not Table 2 Serum levels of DL-8280 after a single oral administration
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL
Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date 1958-01 URL http://hdl.handle.net/2433/111559 Right Type Departmental Bulletin
ON A FEW INFLUENCES OF THE DENTAL CARIES IN THE ELEMENTARY SCHOOL PUPIL BY Teruko KASAKURA, Naonobu IWAI, Sachio TAKADA Department of Hygiene, Nippon Dental College (Director: Prof. T. Niwa) The relationship
Fig. 1 Chemical structure of norfloxacin Table 1. Institutes attended to the study The Department of Dermatology, Defense Medical College The Department of Dermatology, School of Medicine, Teikyo University
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
Fig. 1 Chemical structure of norfioxacin (AM-715)
Fig. 1 Chemical structure of norfioxacin (AM-715) Table 1 Serum and biliary concentration of norfloxacin (AM-715) Table 2 Protocol for clinical evaluation of norfloxacin (AM-715) in the treatment of biliary
CHEMOTHERAPY Silver sulfadiazine (T 107) CHEMOTHERAPY Fig. 1 Item of patients Table 1 Criteria of bacteriological efficacy by the Committee xcellent: E Score of infection becomes to 0% at the end of medication.
Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)
Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
EVALUATION OF NOCTURNAL PENILE TUMESCENCE (NPT) IN THE DIFFERENTIAL DIAGNOSIS OF IMPOTENCE Masaharu Aoki, Yoshiaki Kumamoto, Kazutomi Mohri and Kazunori Ohno Department of Urology, Sapporo Medical College
2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1
2108 CHEMOTHERAPY SEPT. 1977 Table 1 Antimicrobial spectrum Fig. 1 VOL. 25 NO. 7 CHEM 014 HERAPY 2109 Table 2 Susceptibility distribution of Staphylococcus aureus to aminoglycosides (54 strains) Table
日本職業・災害医学会会誌第51巻第1号
内野ら 下腿骨骨折におけるハイブリッド創外固定器の有用性 31 図 2 軟部組織損傷程度と機能成績 Gustilo IIIB 以上の開放骨折では Gustilo IIIA 以下の開放骨折 及び皮下骨折よりも明らかに機能低下が認められた 図 1 年齢と機能成績 60 歳未満の若年者の方が明らかに良好な成績を示した a b c 図 3 a Gustilo Type IIIB b, c AO 分類 Type
indd
24 61 1 2011 調査 研究 1 2 1 1 2 4 1 3 4 1 2 1 2 1 2 1 2 2 1 1 2 3 4 2010 11 11 2011 1 7 Infection Control in an Endoscopy Room Multi - society Guideline and Current Status at Fukushima Medical University
Yogo
2011 Vol.53 No.5 Yogo Jpn J School Health Jpn J School Health Yogo Graduate School of Education, Okayama University Division of Developmental Studies and Support, Graduate School of Education, Okayama
2011 Vol.53 No.2 Jpn J School Health Jpn J School Health Tokushima University Ibaraki University Nihon University Jpn J School Health Jpn J School Health Jpn J School Health Jpn J School Health Graduate
Graduate School of Clinical Psychology, Kibi International University 8 Iga-machi, Takahashi, Okayama, Japan(716-8508) Research Institute of Clinical Psychology, Kibi International University Department
表紙ＰＤＦ作成用／ＰＤＦ表紙作成用
2008 Vol.50 No.1 Jpn J School Health Jpn J School Health Jpn J School Health Jpn J School Health Hosen Junior High School, Okayama City Notre Dame Seishin University Graduate School Jpn J School Health
Osamu NEMOTO, M.D. Clinical and Bacteriological Research of Sucrose/ Povidone-Iodine Ointment (U-PASTA kowa) for Pressure Sores and Skin Ulcers Osamu Nemoto Department of Dermatology,Tonan Hosptal
Takeji NISHIKAWA, M. D.*, Takashi HARADA, M. D.** and Tatsuya IZUML M. D. Toshiyuki SUGI, M. D. Hiroshi HANYAKU, M. D. Shun-ichi MIYAKAWA, M. D. and Masaru TANAKA, M. D. Nobuko INAMOTO, M. D. and Hironori
CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac
CHEMOTHERAPY DEC. 1988 phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepacia 1 Bacteroides bivius Propionibacterium granulosum
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursi
The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursing Professionals for Diabetic Outpatients Not Using
The Journal of the Japan Academy of Nursing Administration and Policies Vol 12, No 1, pp 49 59, 2008 資料 看護師におけるメンタリングとキャリア結果の関連 Relationship between M
The Journal of the Japan Academy of Nursing Administration and Policies Vol 12, No 1, pp 49 59, 2008 資料 看護師におけるメンタリングとキャリア結果の関連 Relationship between Mentoring and Career Outcomes of Nurses 今堀陽子 1) 作田裕美
Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;